Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 67 points (0.4%) at 16,436 as of Friday, Aug. 8, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,992 issues advancing vs. 961 declining with 169 unchanged. The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.4%. Top gainers within the industry include Medivation ( MDVN), up 9.5%, Illumina ( ILMN), up 4.5%, Vertex Pharmaceuticals ( VRTX), up 1.9%, Valeant Pharmaceuticals International ( VRX), up 1.4% and Alexion Pharmaceuticals ( ALXN), up 1.4%. On the negative front, top decliners within the industry include Teva Pharmaceutical Industries ( TEVA), down 1.2%, Novo Nordisk A/S ( NVO), down 0.6% and Abbott Laboratories ( ABT), down 0.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Celgene ( CELG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Celgene is up $0.61 (0.7%) to $85.83 on light volume. Thus far, 1.1 million shares of Celgene exchanged hands as compared to its average daily volume of 4.8 million shares. The stock has ranged in price between $85.15-$86.10 after having opened the day at $85.21 as compared to the previous trading day's close of $85.22. Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $68.9 billion and is part of the health care sector. Shares are up 0.9% year-to-date as of the close of trading on Thursday. Currently there are 17 analysts who rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, robust revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Celgene Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.